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Metallo-β-lactamase (MBL) production usually results in high-level resistance to 
most β-lactams, and a rapid spread of MBL producing major gram-negative patho-
gens is a matter of particular concern worldwide. However, clinical data are scarce 
and most studies compared MBL producer (MP) with MBL non-producer (MNP) 
strains which included carbapenem susceptible isolates. Therefore, we collected 
clinical data of patients in whom imipenem-nonsusceptible Pseudomonas aerugi-
nosa (PA) and Acinetobacter baumannii (AB) were isolated from sputum or urine, 
and investigated MBL production and the risk factors related with MBL acquisi-
tion. The antimicrobial susceptibility patterns were also compared between MPs 
and imipenem-nonsusceptible MNPs (INMNP). Among the 176 imipenem-nonsus-
ceptible isolates, 12 MPs (6.8%) were identified. There was no identifiable risk fac-
tor that contributed to the acquisition of MPs when compared to INMNPs, and 
case-fatalities were not different between the two groups. The percentage of suscep-
tible isolates was higher among MPs for piperacilin/tazobactam and fluoroquino-
lones while that of ceftazidime was higher in INMNPs (p < 0.05). As regards to az-
treonam, which has been known to be a uniquely stable β-lactam against MBLs, 
susceptibility was preserved in only two isolates (16.7%) among MPs, and was not 
higher than that of INMNPs (23.2%). In conclusion, the contribution of MBLs to 
imipenem non-susceptibility in PA/ABs isolated from sputum and urine was rela-
tively limited, and there was no significant risk factor associated with acquisition of 
MPs compared with INMNPs. However, limited susceptibility to aztreonam im-
plies that MPs may hold additional resistance mechanisms, such as extended spec-
trum β-lactamases, AmpC β-lactamases, or other non-enzymatic mechanisms.
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(cloverleaf) test, using MacConkey agar instead of the pre-
viously used Mueller-Hinton agar.10 MBL production was 
screened by the double-disk synergy test using an imipen-
em disk and an EDTA (750 μg) plus sodium mercaptoace-
tic acid (SMA, 2 mg) disk on Mueller-Hinton agar with 10 
mm distance from the edge to the edge of the disk.10 Com-
mercial imipenem disks and media (Becton-Dickinson, 
Sparks, MD, USA) were used for these tests, while the 
EDTA-SMA disks were prepared from commercially avail-
able chemicals (Sigma Chemical, St. Louis, MO, USA). 
The blaIMP-1, blaVIM-2 and blaSIM-1 alleles were detected by 
polymerase chain reaction (PCR) among the screening pos-
itive isolates as described previously11 and the primers used 
were: IMP1-F 5’-CAT GGT TTG GTG GTT CTT GT-3’, 
IMP1-R 5’-ATA ATT TGG CGG ACT TTG GC-3’, VIM2-
F 5’-ATG TTC AAA CTT TTG AGT AAG-3’, VIM2-R 
5’-CTA CTC AAC GAC TGA GCG-3’, SIM1-F 5’-TAC 
AAG GGA TTC GGC ATC G-3’ and SIM1-R 5’-TAA 
TGG CCT GTT CCC ATG TG-3’.  
To perform the pulsed field gel electrophoresis (PFGE), 
genomic DNA of MBL-producing PA and AB was digested 
with XbaI and SmaI, respectively, as suggested by the man-
ufacturer. Fragments were separated for 20 hours at 6 V/cm 
at 11°C using a CHEF-DR II system (Bio-Rad, Hercules, 
CA, USA). ProMega-Markers Lambda Ladders G3011 
(Promega, WI, USA) was used for molecular mass marker.
To identify risk factors contributing to MBL producer ac-
quisition, we reviewed age, gender, Charlson index, APA-
CHE II score, underlying illness, the entire hospital stay pe-
riod including multiple admissions within six months prior to 
isolation, intensive care unit (ICU) stay, ventilator care, and 
antibiotics exposure prior to isolation such as piperacillin/
tazobactam, cefoperazone/sulbactam, aztreonam, fluoroqui-
nolones, aminoglycosides, glycopeptides, ceftazidime, and 
carbapenems. ICU stay, ventilator care and antibiotic expo-
sure were included when each factor lasted more than 48 
hours within 28 days prior to isolation. Neutropenia (abso-
lute neutrophil count < 1,000 mm3), immunosuppression 
(administration of cytostatic agent or glucocorticoid equiv-
alent or more potent than methylprednisolone 20 mg per 
day for more than 14 days), and antineoplastic treatment 
within 3 months prior to the isolation were also investigat-
ed. To assess the outcome, 28-day case-fatality after isola-
tion and in hospital case-fatality were analyzed. Statistical 
analyses were performed by SAS version 9.1.3 (SAS Insti-
tute, Inc., Cary, NC, USA). All tests were two-tailed, and a 
p value < 0.05 was considered significant.  
β-lactam antibiotics. Particularly, the emergence of ac-
quired metallo-β-lactamase (MBL) among major gram-
negative pathogens [Pseudomonas aeruginosa (PA), Aci-
netobacter spp., Enterobacteriaceae] is a matter of particular 
concern on account of their rapid spread and increasing di-
versity/number of species involved.1 However, limited clin-
ical data are available regarding to the clinical significance 
of infections caused by these strains. Several studies have 
demonstrated that MBL producer (MP) acquisition is asso-
ciated with increased mortality in PA infection.2-5 However, 
carbapenem susceptible strains are included in MBL non-
producer (MNP) in most studies, thus revealing higher 
mortality in the MBL producing group. It is well known 
that acquisition of carbapenem resistance is associated with 
increased mortality in PA and Acinetobacter baumannii 
(AB) infections.6,7 Therefore, to characterize the MBL pro-
duction itself rather than carbapenem resistance, we com-
pared MBL producing PA/AB and imipenem-nonsuscepti-
ble MNPs (INMNP) isolated from respiratory and urinary 
tracts which are common sites of clinical infections and 
sources of nosocomial spread. 
The microbiology laboratory database was reviewed, and 
we selected imipenem-nonsusceptible PA and AB which 
had been isolated from sputum or urine for the purpose of 
microbiologic diagnosis irrespective of hospitalization be-
tween January 2007 and June 2007 in a single 2,000-bed 
tertiary hospital in Seoul, Republic of Korea. Clinical data 
for the source patients of the isolates were collected by a 
retrospective analysis of the electronic medical records, and 
patients were excluded from the analysis if medical records 
prior to the isolation were not sufficient (e.g., transfer from 
another hospital). Patients without available follow-up data 
after discharge were also excluded from the analysis. Iso-
lates referred from outpatient departments (OPD) were in-
cluded if sufficient medical history was available. All the 
isolates that had been related with both clinical infections or 
colonization of the respiratory or urinary tracts were con-
sidered eligible for the study. Only the first isolate from 
each patient was included in the analysis.
The PA/AB strains were identified using conventional 
techniques and/or ATB 32 GN system (BioMérieux, Mar-
cy-l’Étoile, France).8 The antimicrobial susceptibility was 
determined using a disk-diffusion method. Results were in-
terpreted using the guidelines of the Clinical and Laborato-
ry Standards Institute.9
Among the imipenem-nonsusceptible isolates, carbapen-
emase production was screened by the imipenem disk Hodge MBL Producing Gram-Negative Bacilli from Sputum and Urine
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During the study period, 432 PA (340 from 
sputum and 92 from urine) and 199 AB (159 
from sputum and 40 from urine) non-repeti-
tive isolates were identified. Among them, 
187 (29.6%) were imipenem non-susceptible 
(130 PA and 57 AB). Eleven isolates were ex-
cluded from the analysis because of inade-
quate availability of their medical records. Fi-
nally, 176 isolates consisting of 123 PA (102 
from sputum and 21 from urine) and 53 AB 
(48 from sputum and 5 from urine) were ana-
lyzed. The proportion of sources (sputum and 
urine) was not different between PA and AB 
(p = 0.19, data not shown). 
MBL production was identified in 12 iso-
lates by PCR (6.8%)(Table 1). The blaVIM-2 was 
the most common MBL type (75%, 6 of 7 PA 
and 3 of 5 AB); two blaIMP-1 and one blaSIM-1 se-
quences were identified in MPs. The propor-
tions of susceptible strains among MPs were 
41.7% for piperacillin/tazobactam, fluoroqui-
nolones, and aminoglycosides while few iso-
lates proved to be susceptible to aztreonam 
(16.7%) and ceftazidime (8.3%). In PFGE 
analysis, 5 AB isolates revealed different pat-
terns (Fig. 1). However, 2 isolates among the 7 
MBL-producing PA revealed identical PFGE 
patterns. They were obtained 14 days apart 
from an inpatient of a rehabilitation center and 
an outpatient who was regularly visiting OPD 
of the same center. This last patient was the 
only one whose culture study was referred from 
OPD among the 176 imipenem nonsusceptible 
PA and AB isolates in our study. The propor-
tion of MPs among imipenem non-susceptible 
isolates was not different according to the spe-
cies (PA 5.7%/AB 9.4%). However, urine had 
higher proportion of MP among imipenem 
non-susceptible isolates than sputum (26.9% 
vs. 3.3%, p < 0.001). 
With regard to the risk factors associated 
with MP acquisition, we compared baseline 
characteristics, underlying morbidity and use 
of antibiotics within 28 days prior to isolation 
between MPs and INMNPs (Table 2). ICU 
stay (70.1% vs. 25%, p = 0.003) and mechan-
ical ventilator care prior to PA/AB isolation 
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MBL-producing strains are sparse. Analysis of the antimi-
crobial chemotherapy administrated before isolation of 
MPs often revealed that many patients had not been admin-
istered with carbapenems, but fluoroquinolones3,13 and 
β-lactam antibiotics.3,14,15 Other reports suggested carbapen-
em use, ICU stay > 20 days,15 underlying neurologic disor-
der, urinary tract infection, renal failure,3 and neutropenia14 
as contributing factors. However, all of the above men-
tioned studies compared an MP group with an MNP group 
irrespective of the susceptibility to carbapenems, which are 
now considered as a key drug for the treatment of gram-
negative bacilli due to the apparently high barrier to resis-
tance acquisition. Therefore, we chose to compare an MP 
group with an INMNP group rather than with a mere MNP 
group that includes carbapenem susceptible isolates. Al-
though we failed to identify any significant risk factor, this 
result might be related to the limited number of MPs in our 
study population. Further investigation is required to ex-
plain this aspect. 
We could not investigate the MP acquisition-related mor-
tality because our cases included not only clinical infec-
tions, but also colonization. Some authors2,4,5 have reported 
higher mortality in an MP group. However, they compared 
the group with MNPs irrespective of carbapenem sensitivi-
ty. Although Laupland, et al.16 observed higher mortality in 
MBL-producing PA infected patients than in the MBL-non-
producing carbapenem resistant group, more data are re-
quired to ascertain the impact of MBL acquisiton on mor-
tality. In a recent study, for example, carbapenem resistance, 
advanced age, and severity of underlying disease were sug-
gested as independent risk factors for mortality, but not 
VIM-1 type MBL production among Klebsiella pneumoni-
ae bloodstream infection patients.17 
As regards to the susceptibility of antibiotics other than 
imipenem, aztreonam is generally an exception, while MBL 
production results in high-level resistance to most β-lactam 
antibiotics. However, equivalent resistance profiles for az-
treonam have been observed between the MP group and the 
MNP group in previous reports.3,18,19 Our study also revealed 
higher percentage of resistance to aztreonam in the MP 
group. Resistance to aztreonam in MPs might be explained 
by extended spectrum β-lactamases (ESBL),20,21 AmpC 
β-lactamases,22-24 or other non-enzymatic mechanisms23 as 
described before. Therefore, aztreonam may not be an ex-
ceptionally useful β-lactam antibiotic for the treatment of 
MPs in current clinical settings.
The portion of strains showing susceptibility for piper-
(56.6% vs. 25%, p = 0.034) were more frequent in the 
INMNP group. Exposure to antibiotics was also more fre-
quent in the INMNP group (76.2% vs. 41.7%, p = 0.015). 
In the analysis of individual antibiotics, exposure to piper-
acillin/tazobactam was significantly more frequent in the 
INMNP group. Therefore, it was not possible to identify 
significant risk factor related with MP acquisition among 
imipenem nonsusceptible isolate acquired patients. Twenty-
eight-day and in-hospital case-fatalities after imipenem 
nonsusceptible isolates acquisition revealed no difference 
between MPs and INMNPs. 
With regard to the susceptibilities to the six antibiotics 
which were frequently used for treatment of PA and AB 
other than carbapenem (Table 3), the proportions of suscep-
tible isolates were higher in the MP group for more than 
half of the analyzed drugs, and those of piperacillin/tazo-
bactam and fluoroquinolones showed statistically signifi-
cant differences. Regarding to ceftazidime, only one strain 
(8.3%) was susceptible among MPs, and this proportion 
was significantly lower than that of INMNPs (61.7%), 
which is comparable with previous report.12 However, the 
aztreonam susceptibility which is known to be uniquely 
spared among β-lactams against MBL was preserved in 
only 2 isolates (16.7%) among MPs, and it was not more 
frequent than that of INMNPs (23.2%). 
As mentioned above, the clinical data concerning risk 
factors and treatment outcomes of infections caused by 
Fig. 1. Pulsed field gel clectrophoresis (PFGE) analysis of metallo-β-
lactamase (MBL)-producing Pseudomonas aeruginosa (A) and Acineto-
bacter baumannii (B). Two isolates of Pseudomonas aeruginosa (case no. 
1 and no. 2) revealed identical patterns. One of them was an inpatient and 
the other an outpatient of the same center. The numbers on top of each fig-
ure refer to the case numbers described in Table 1. Lane M, molecular 
weight marker (kb).  
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be related to our study group which included not only pa-
tients with clinical infections but also patients with coloni-
zation. 
 In PFGE analysis, two isolates which were obtained 14 
acillin/tazobactam and fluoroquinolones were higher among 
MPs, and overall prior antibiotics exposure was more fre-
quent in the INMNP group. These findings are not consis-
tent with previous reports,3,16,18 and the discrepancies might 
Table 2. Comparison between MBL-Producers and MBL-Nonproducers
MBL-nonproducers
n = 164 (93.2)
MBL-producers
n = 12 (6.8)
p value
Mean age (yrs) 55.19 47.42 0.353
Male sex 112 (68.3) 7 (58.3) 0.529
Hospital stay within 6 months (days)* 38.62 34.58 0.793
Species
    Pseudomonas aeruginosa 116 (70.7) 7 (58.3)
    Acinetobacter baumannii   48 (29.3) 5 (41.7) 0.350
Charlson index (mean) 2.15 2.00 0.803
APACHE II score (mean) 9.79 7.08 0.100
Underlying disease
     Malignancy   41 (25.0) 4 (33.3) 0.506
     Diabetes mellitus   46 (28.0) 2 (16.7) 0.519
     Renal disease   24 (14.6) 1 (8.3) 0.455
     Cardiac disease   33 (20.2) 2 (16.7) 1.000
     Liver cirrhosis     9 (5.5) 0 1.000
Neutropenia     3 (3.1) 0 1.000
Immunosuppression   32 (19.6) 5 (41.7) 0.133
ICU stay 115 (70.1) 3 (25) 0.003
Ventilator care   91 (56.6) 3 (25) 0.034
Previous antibiotics exposure 119 (72.6) 5 (41.7) 0.015
    Piperacillin/tazobactam   43 (26.2) 0 0.040
    Cefoperazone/sulbactam   29 (17.7) 0 0.220
    Aztreonam     2 (1.2) 0 1.000
    Fluoroquinolones   63 (38.4) 2 (16.7) 0.215
    Aminoglycosides   42 (25.6) 3 (25) 1.000
    Glycopeptides   78 (47.6) 3 (25) 0.148
    Ceftazidime   15 (9.1) 0 0.603
    Carbapenem   56 (34.1) 2 (16.7) 0.341
28-day case-fatality   26 (15.6) 1 (8.3) 0.696
In hospital case-fatality   59 (36.0) 2 (16.7) 0.221
MBL, metallo-β-lactamase; ICU, intensivecareunit.
*All hospital stay duration within 6 months prior to imipenem nonsusceptible organism isolation were added including multiple admis-
sions. The data are the numbers (%) of patients unless otherwise indicated. 
Table 3. Susceptibility to Antibiotics Other Than Carbapenem
MBL-nonproducers
n = 164 (93.2)
MBL-producers
n = 12 (6.8)
p value
 Piperacillin/tazobactam   27 (16.5)   5 (41.7)    0.045
 Cefaperazone/sulbactam   35 (21.3)   4 (33.3)    0.305
 Aztreonam   38 (23.2)   2 (16.7)    1.000
 Fluoroquinolones   20 (12.2)   5 (41.7)    0.015
 Aminoglycosides   51 (31.1)   5 (41.7)    0.524
 Ceftazidime 102 (62.2) 1 (8.3) < 0.001
MBL, metallo-β-lactamase.
The data are the numbers (%) of patients unless otherwise indicated.Bum Sik Chin, et al.
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tion on mortality in nosocomial Pseudomonas aeruginosa infec-
tions. J Antimicrob Chemother 2006;58:387-92.
3. Zavascki AP, Barth AL, Gaspareto PB, Gonçalves AL, Moro AL, 
Fernandes JF, et al. Risk factors for nosocomial infections due to 
Pseudomonas aeruginosa producing metallo-beta-lactamase in 
two tertiary-care teaching hospitals. J Antimicrob Chemother 
2006;58:882-5.
4. Hirakata Y, Yamaguchi T, Nakano M, Izumikawa K, Mine M, 
Aoki S, et al. Clinical and bacteriological characteristics of IMP-
type metallo-beta-lactamase-producing Pseudomonas aeruginosa. 
Clin Infect Dis 2003;37:26-32.
5. Zavascki AP, Barth AL, Fernandes JF, Moro AL, Gonçalves AL, 
Goldani LZ. Reappraisal of Pseudomonas aeruginosa hospital-ac-
quired pneumonia mortality in the era of metallo-beta-lactamase-
mediated multidrug resistance: a prospective observational study. 
Crit Care 2006;10:R114.
6. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, 
Fishman NO. Imipenem resistance among pseudomonas aerugi-
nosa isolates: risk factors for infection and impact of resistance on 
clinical and economic outcomes. Infect Control Hosp Epidemiol 
2006;27:893-900.
7. Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, et al. 
Impact of imipenem resistance on mortality in patients with Aci-
netobacter bacteraemia. J Antimicrob Chemother 2007;59:525-30.
8. Murray EJ, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. Man-
ual of clinical microbiology. 7th ed. Washington DC: ASM Press; 
1999. p.442-58.
9. Performance standards for antimicrobial susceptibiliy testing; Nine-
teenth Informational Supplement. 2009;CLSI document M100-S19. 
10. Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the 
Hodge test and the imipenem-EDTA double-disk synergy test for 
differentiating metallo-beta-lactamase-producing isolates of Pseu-
domonas spp. and Acinetobacter spp. J Clin Microbiol 2003;41: 
4623-9.
11. Lee K, Yum JH, Yong D, Lee HM, Kim HD, Docquier JD, et al. 
Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a 
class 1 integron from Acinetobacter baumannii clinical isolates 
from Korea. Antimicrob Agents Chemother 2005;49:4485-91.
12. Lee K, Ha GY, Shin BM, Kim JJ, Kang JO, Jang SJ, et al. Metal-
lo-beta-lactamase-producing Gram-negative bacilli in Korean Na-
tionwide Surveillance of Antimicrobial Resistance group hospitals 
in 2003: continued prevalence of VIM-producing Pseudomonas 
spp. and increase of IMP-producing Acinetobacter spp. Diagn Mi-
crobiol Infect Dis 2004;50:51-8.
13. Nouér SA, Nucci M, de-Oliveira MP, Pellegrino FL, Moreira BM. 
Risk factors for acquisition of multidrug-resistant Pseudomonas 
aeruginosa producing SPM metallo-beta-lactamase. Antimicrob 
Agents Chemother 2005;49:3663-7.
14. Kim YA, Choi JY, Kim CK, Kim CO, Kim MS, Choi SH, et al. 
Risk factors and outcomes of bloodstream infections with metallo-
beta-lactamase-producing Acinetobacter. Scand J Infect Dis 
2008;40:234-40.
15. Horianopoulou M, Legakis NJ, Kanellopoulou M, Lambropoulos 
S, Tsakris A, Falagas ME. Frequency and predictors of coloniza-
tion of the respiratory tract by VIM-2-producing Pseudomonas ae-
ruginosa in patients of a newly established intensive care unit. J 
Med Microbiol 2006;55:1435-9.
16. Laupland KB, Parkins MD, Church DL, Gregson DB, Louie TJ, 
Conly JM, et al. Population-based epidemiological study of infec-
tions caused by carbapenem-resistant Pseudomonas aeruginosa in 
days apart revealed identical PFGE patterns in 7 MBL pro-
ducing PA. A direct contact between the two patients was 
not identified. However, one source of major concern is the 
ability of MBLs to spread rapidly which has been observed 
in various clinical circumstances.2,25,26 The above cases 
could be an example of the potential clonal spread of MPs, 
although the majority of MPs occurred sporadically in our 
institution, and contribution of MBL to carbapenem resis-
tance was limited, similar to other study performed in the 
same country.27  
 In conclusion, the contribution of MBL to imipenem re-
sistance in PA/AB isolated from sputum and urine was rela-
tively limited in our institution, and there was no identifi-
able risk factor associated with MPs acquisition, compared 
with INMNPs. However, the limited susceptibility to aztre-
onam in the MP group implies that MBL producing strains 
commonly carry other resistance mechanisms such as ES-
BLs, AmpC β-lactamases, and other non-enzymatic mecha-
nisms. 
Our study has several limitations. First, the number of MPs 
used for the study was small, and that could have impaired 
our ability to identify significant risk factors associated with 
acquisition of MPs. Subgroup analysis according to isola-
tion sources was also not feasible because of the small size 
of the population under investigation. Second, we included 
all isolates from the respiratory and urinary tract, therefore, 
our results might not be generalized as overt clinical infec-
tions. Further analysis of a significant number of infection 
cases is required to more accurately assess the clinical im-
pact of MPs.
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